In a triple-negative breast cancer (TNBC) mouse model, combined treatment with metformin and PD-1 antibodies significantly inhibited tumor growth and metastasis, increased CD8+ T cell infiltration, and reduced PD-L1 expression, indicating synergistic antitumor effects of the combination (68). This evidence concerns the gene CD274 and neoplasm.